SEC Form 4 · accession 0001209191-17-028213
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Louise Collins
Officer — SVP and Chief Medical Officer
Period of report
Apr 24, 2017
Accepted (ET)
Apr 26, 2017 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 24, 2017 | A | 1,250 | $0.00 | A | 25,156 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of March 20, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.